RP-HPLC method development and validation for the simultaneous estimation of glecaprevir and pibrentasvir in bulk and tablet dosage form

RP-HPLC method development and validation for the simultaneous estimation of glecaprevir and pibrentasvir in bulk and tablet dosage form - Development and Validation of the RP-HPLC Method for Concurrent Estimation of Glecaprevir and Pibrentasvir in Tablet Dosage Forms. Pibrentasvir and glicaprevir's medicinal dosage forms were identified using the RP-HPLC analytical method. The chromatographic separation was performed using an Altima C18 150 x 4.6 mm, 5 µm and a mobile phase consisting of buffer 0.1% OPA: Acetonitrile (60:40) (v/v). 0.1% OPA was the buffer utilised in this procedure. Without derivatisation, detection was done at 260.0 nm with a flow rate of 1 ml/min. Both pibrentasvir and glicaprevir were shown to be linear over the 45–105 µg/mL and 125–325 µg/mL ranges, respectively. Using the linear regression equation y = 9124x + 494.7 (r?2; = 0.998) for Glecaprevir and y = 13172x + 8283 (r?2; = 0.998) for Pibrentasvir, it was shown that this linearity was -134 for both drugs. The calibration curve produced a linear area under the curve for Glecaprevir and Pibrentasvir. In accordance with the schedule, the computed retention time was 3.140 (2%) and 2.249 minutes. Glecaprevir and Pibrentasvir were found to have respective % RSDs of 0.3 and 0.4. The anticipated LOD and LOQ values of 0.040, 0.121, and 0.0791, 0.241%, respectively, were obtained from this validation. The range of recovery (%Recovery) was 99.63% to 99.53%. The recovery (%Recovery) ranged from 99.63% to 99.53%. Following statistical validation, the robustness of the proposed technique ranged from 1.236 to 2.636. The recovery range of 99.63 to 99.53% suggests that the strategy was suitable. Regular quality control testing in industries could make use of the suggested RP-HPLC technology due to its affordability, accuracy, precision, and ease of use. Keywords: Glecaprevir, Pibrentasvir, HPLC, Retention time, Degradation studies.

Authors

Institutions

Publication Details

Journal
International Journal of Pharmaceutical Chemistry and Analysis
Published
2025-04-15
DOI
https://doi.org/10.18231/j.ijpca.2025.009
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RP-HPLC method development and validation for the simultaneous estimation of glecaprevir and pibrentasvir in bulk and tablet dosage form

B. L. Ramakrishna, Ramachandra Bandi, Chelladurai Prem Kumar
International Journal of Pharmaceutical Chemistry and Analysis
Analytical Methods in Pharmaceuticals
article

RP-HPLC method development and validation for the simultaneous estimation of glecaprevir and pibrentasvir in bulk and tablet dosage form

B. L. Ramakrishna, Ramachandra Bandi, Chelladurai Prem Kumar
article en

Abstract

RP-HPLC method development and validation for the simultaneous estimation of glecaprevir and pibrentasvir in bulk and tablet dosage form - Development and Validation of the RP-HPLC Method for Concurrent Estimation of Glecaprevir and Pibrentasvir in Tablet Dosage Forms. Pibrentasvir and glicaprevir's medicinal dosage forms were identified using the RP-HPLC analytical method. The chromatographic separation was performed using an Altima C18 150 x 4.6 mm, 5 µm and a mobile phase consisting of buffer 0.1% OPA: Acetonitrile (60:40) (v/v). 0.1% OPA was the buffer utilised in this procedure. Without derivatisation, detection was done at 260.0 nm with a flow rate of 1 ml/min. Both pibrentasvir and glicaprevir were shown to be linear over the 45–105 µg/mL and 125–325 µg/mL ranges, respectively. Using the linear regression equation y = 9124x + 494.7 (r?2; = 0.998) for Glecaprevir and y = 13172x + 8283 (r?2; = 0.998) for Pibrentasvir, it was shown that this linearity was -134 for both drugs. The calibration curve produced a linear area under the curve for Glecaprevir and Pibrentasvir. In accordance with the schedule, the computed retention time was 3.140 (2%) and 2.249 minutes. Glecaprevir and Pibrentasvir were found to have respective % RSDs of 0.3 and 0.4. The anticipated LOD and LOQ values of 0.040, 0.121, and 0.0791, 0.241%, respectively, were obtained from this validation. The range of recovery (%Recovery) was 99.63% to 99.53%. The recovery (%Recovery) ranged from 99.63% to 99.53%. Following statistical validation, the robustness of the proposed technique ranged from 1.236 to 2.636. The recovery range of 99.63 to 99.53% suggests that the strategy was suitable. Regular quality control testing in industries could make use of the suggested RP-HPLC technology due to its affordability, accuracy, precision, and ease of use. Keywords: Glecaprevir, Pibrentasvir, HPLC, Retention time, Degradation studies.

International Journal of Pharmaceutical Chemistry and AnalysisVol. 12(1)
Government of Andhra Pradesh (IN), Indian Institute of Technology Tirupati (IN), Yogi Vemana University (IN)
Openalex Percentile: Top 91%
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.